gefapixant

From Aaushi
Jump to navigation Jump to search

Indications

* FDA rejects approval, benefit not clinically meaningful

Dosage

Mechanism of action

Clinical trials

  • in phase 3 trial

More general terms

References

  1. Boyles S Gefapixant Reduces Chronic Cough in Phase III Trials - But taste distortion was frequent AE at active dosage. MedPage Today September 9, 2020 https://www.medpagetoday.com/meetingcoverage/ers/88515
  2. Short E Drug Candidate for Chronic Cough Rejected by FDA Panel. Gefapixant's benefit not clinically meaningful enough, panelists say MedPage Today November 17, 2023 https://www.medpagetoday.com/pulmonology/generalpulmonary/107440

Database